Athenex, Inc. (ATNX)

Oncology Corporate Profile

Stock Performance

0.0000
0.0000

3 Month Stock History Chart

HQ Location

1001 Main Street, Suite 600
Buffalo, NY 14203

Company Description

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of Athenex’s proprietary research and selection processes in the lab.

Website: http://www.athenex.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
oraxolP-gp + chemo-therapeutic agentBreast cancerIII
oraxol (+ ramucirumab)P-gp + chemo-therapeutic agent2nd line Gastric cancerI
KX-02Src kinase inhibitorGlioblastoma Multiforme (GBM)I
KX-01Src kinase inhibitorOvarian cancerI
oratecanP-gp + chemo-therapeutic agentVarious cancer typesI
oradoxelP-gp + chemo-therapeutic agentVarious cancer typesI

Source: http://www.athenex.com/

Recent News Headlines

There are no news items to display